The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2016

Filed:

Jun. 11, 2014
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);

Inventors:

John Chiorini, Dayton, MD (US);

Melodie L. Weller, Silver Spring, MD (US);

Michael Schmidt, Kensington, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); C12N 15/00 (2006.01); C07H 21/04 (2006.01); A61K 48/00 (2006.01); C07K 14/71 (2006.01); C12N 15/86 (2006.01); A61K 31/522 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 31/522 (2013.01); A61K 45/06 (2013.01); A61K 48/0008 (2013.01); C07K 14/71 (2013.01); C12N 15/86 (2013.01); C07H 21/04 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01);
Abstract

Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.


Find Patent Forward Citations

Loading…